SRR10900561
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.600
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.600
- DNA_REPAIR+0.400
- MITOTIC_SPINDLE+0.300
- MTORC1_SIGNALING+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- GLYCOLYSIS+0.100
- NOTCH_SIGNALING+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.500
- COAGULATION-0.400
- ESTROGEN_RESPONSE_EARLY-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- APICAL_SURFACE-0.300
- BILE_ACID_METABOLISM-0.300
- COMPLEMENT-0.300
- ESTROGEN_RESPONSE_LATE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.936 |
| 2 | BS_N6N147BY | Embryonal tumors | — | 0.932 |
| 3 | BS_R439VVPK | medulloblastoma | — | 0.921 |
| 4 | SAMN03290940 | — | — | 0.920 |
| 5 | BS_HE57E1RP | medulloblastoma | — | 0.919 |
| 6 | AUR-AG0N-TTM1-A-1-1-R-A743-41 | — | E | 0.917 |
| 7 | BS_K25F4J3V | ATRT | — | 0.917 |
| 8 | TCGA-55-7570-01A-11R-2039-07 | — | cohortA3 | 0.916 |
| 9 | TCGA-XF-A9ST-01A-11R-A42T-07 | — | — | 0.914 |
| 10 | ERR2598212 | fetal | fetal | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |